Clinical Trials Browser

Peripheral Nervous System Diseases × Genitourinary × Clear all

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02492360 2018-02-28

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

Withdrawn

Genitourinary

Peripheral Nervous System Diseases, Testicular Neoplasms

NCT00365768 2016-09-09

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

Phase 2 Completed

56 enrolled 5 charts

GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Neurotoxicity Syndromes, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

P-EVOLUTION

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors